Compare BioNTech SE - ADR (BNTX) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Wells Fargo & Co — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Wells Fargo & Co trades at $88.97 (market cap $264.66B). The key difference: Wells Fargo & Co is far larger — about 11.4× BioNTech SE - ADR's market cap, and Wells Fargo & Co pays a 2.29% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | WFC | |
|---|---|---|
Market Cap | $23.31B | $264.66B |
Sector | Health | Financials |
52-Week High | $119.34 | $96.40 |
52-Week Low | $83.89 | $73.42 |
Enterprise Value | $6.60B | — |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Wells Fargo (WFC) trades at $89.15, up 1.82% for the day, with a bullish technical signal from moving averages and a consensus analyst price target of $97.64. Recent earnings show a Q2 2026 beat but misses in prior quarters, while revenue and net income have grown steadily from 2022 to 2025. The company is expanding into digital services like tokenized deposits, announced in August 2026, to enhance corporate client offerings.
The stock presents a value opportunity with a P/E of 12.72 and strong profitability metrics, including a 25.97% net income margin. Risks include volatile cash flows, with operating cash flow negative in 2025, and competitive pressures in banking. Analyst sentiment is mixed but leans positive, with 45% buy ratings, supporting potential upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
